Cite
HARVARD Citation
Camaj, P. et al. (2015). KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. Future oncology. pp. 1919-1929. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Camaj, P. et al. (2015). KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. Future oncology. pp. 1919-1929. [Online].